This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Seattle Genetics' 2nd Cancer Study Win

SEATTLE ( TheStreet) -- Clinical trial victory two for Seattle Genetics' (SGEN - Get Report) lymphoma drug brentuximab vedotin.

Seattle Genetics said Monday that 86% of patients with advanced systemic anaplastic large cell lymphoma (ALCL) responded to treatment with brentuximab, also known as SGN-35. The phase II study enrolled 58 ALCL patients, all of whom had a form of the rare cancer that was no longer responding to currently available therapies. This is the second positive clinical trial for brentuximab announced in as many weeks. On Sept. 27, Seattle Genetics announced positive results from a study in patients with advanced Hodgkin disease.

Seattle Genetics intends to submit brentuximab for U.S. approval in the first half of 2011 as a treatment for both forms of lymphoma. Millennium Pharmaceuticals, the U.S.-based subsidiary of the Japanese drug maker Takeda, is Seattle Genetics' ex-U.S. partner for brentuximab and will be in charge of getting the drug approved in Europe.

ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that expresses a protein known as CD30. Between 2,000 and 3,000 patients are diagnosed with ALCL in the U.S. each year, with about half of those treated effectively with first-line chemotherapy.

Brentuximab is designed using a technology proprietary to Seattle Genetics that delivers a lethal dose of chemotherapy directly to cancer cells while sparing healthy cells from toxic effects. Brentuximab consists of an antibody that attaches itself to the CD30 receptor found on tumor cells. Once inside the tumor, brentuximab releases a toxic chemotherapy payload.

Seattle Genetics closed Friday at $16.77. The stock is up 38% since Sept. 27 when the positive brentuximab data in Hodgkin lymphoma was announced.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SGEN $28.64 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs